NASDAQ: PRPOPrecipio Inc Stock
$26.46+0.02 (+0.08%)
Updated Sep 18, 2026
PRPO Price
$26.46
Fair Value Price
N/A
Market Cap
$47.37M
52 Week Low
$16.14
52 Week High
$33.63
P/E
-41.34x
P/B
3.21x
P/S
1.63x
PEG
N/A
Dividend Yield
N/A
Revenue
$27.20M
Earnings
-$1.22M
Gross Margin
44.1%
Operating Margin
-4.29%
Profit Margin
-4.5%
Debt to Equity
0.45
Operating Cash Flow
$1M
Beta
0.61
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PRPO Overview
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PRPO's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
B
PRPO
Ranked#25 of 38
Ranked#25 of 38
Be the first to know about important PRPO news, forecast changes, insider trades & much more!
PRPO News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PRPO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PRPO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PRPO is good value based on its book value relative to its share price (3.21x), compared to the US Diagnostics & Research industry average (4.57x)
P/B vs Industry Valuation
PRPO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PRPO due diligence checks available for Premium users.
Valuation
PRPO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-41.34x
Industry
10.85x
Market
44.48x
PRPO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.21x
Industry
4.57x
PRPO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PRPO's financial health
Profit margin
Revenue
$7.0M
Net Income
-$219.0k
Profit Margin
-3.1%
PRPO's Earnings (EBIT) of -$1.17M... subscribe to Premium to read more.
Interest Coverage Financials
PRPO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$21.3M
Liabilities
$6.6M
Debt to equity
0.45
PRPO's short-term assets ($6.54M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PRPO's short-term assets ($6.54M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PRPO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PRPO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$660.0k
Investing
-$132.0k
Financing
-$57.0k
PRPO's operating cash flow ($1.10M)... subscribe to Premium to read more.
Debt Coverage Financials
PRPO vs Diagnostic & Research Stocks
Precipio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.